Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the selective degeneration of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and spinal cord. First described by Jean-Martin Charcot in 1869, ALS leads to muscle weakness, spasticity, paralysis, and typically fatal respiratory failure within 2–5 years of symptom onset. The disease affects approximately 3–5 per 100,000 individuals worldwide, with most cases being sporadic (90–95%) while 5–10% are familial with inherited mutations. ALS exists on a spectrum with frontotemporal dementia (FTD), with 10–15% of ALS patients developing FTD and a larger proportion showing subtle cognitive or behavioral changes, reflecting shared neuropathology involving TDP-43 protein aggregation.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the selective degeneration of upper motor neurons in the motor cortex and lower motor neurons in the brainstem and spinal cord. First described by Jean-Martin Charcot in 1869, ALS leads to muscle weakness, spasticity, paralysis, and typically fatal respiratory failure within 2–5 years of symptom onset. The disease affects approximately 3–5 per 100,000 individuals worldwide, with most cases being sporadic (90–95%) while 5–10% are familial with inherited mutations. ALS exists on a spectrum with frontotemporal dementia (FTD), with 10–15% of ALS patients developing FTD and a larger proportion showing subtle cognitive or behavioral changes, reflecting shared neuropathology involving TDP-43 protein aggregation.
The epidemiological features of ALS include a peak onset age of 58–63 years for sporadic cases and slightly earlier for familial forms. Men are affected slightly more than women (ratio approximately 1.5:1), though this difference diminishes with age. Geographic clusters have been identified, including the Chamorro population of Guam and the Kii Peninsula of Japan, where ALS-Parkinsonism-dementia complex occurs at extraordinarily high rates, suggesting environmental and genetic interaction factors. Approximately 5–10% of ALS cases are linked to specific gene mutations, with the most common being a hexanucleotide repeat expansion in the C9ORF72 gene (40–50% of familial ALS), followed by mutations in SOD1 (15–20%), TARDBP (encoding TDP-43, 5–10%), and FUS (5%).
Motor neurons are large, highly specialized cells with extraordinarily long axons that can extend over a meter in length, presenting unique challenges for protein homeostasis, axonal transport, and metabolic support. Upper motor neurons in the layer V pyramidal cells of the motor cortex send corticospinal axons through the internal capsule, brainstem, and spinal cord to synapse onto lower motor neurons, which then project to skeletal muscle fibers at the neuromuscular junction. This Upper-to-Lower motor neuron circuit controls voluntary movement, posture, and breathing.
Motor neuron survival depends on several critical cellular programs including neurotrophic factor signaling (BDNF, GDNF, IGF-1), precise calcium buffering (calcium-binding proteins such as parvalbumin and calbindin), efficient glutamate neurotransmission (with astrocytes normally providing protective glutamate uptake via EAAT2/GLT-1), and robust axonal transport machinery (kinesins, dynein, and associated proteins). Neuromuscular junctions undergo continuous remodeling through the ALS-related proteins MuSK and RAPSN, and motor neurons exhibit exceptionally high metabolic demands with significant mitochondrial activity concentrated at nodes of Ranvier and synaptic terminals.
ALS represents a prototypic example of non-cell-autonomous neurodegeneration, where multiple cell types beyond motor neurons contribute to disease progression. Astrocytes in ALS lose their normal protective functions and acquire toxic properties, releasing inflammatory mediators and failing to clear extracellular glutamate, leading to excitotoxic motor neuron damage. Microglia become chronically activated, producing pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) that accelerate motor neuron death. Oligodendrocytes also degenerate early in ALS, depriving motor neurons of metabolic support as these cells normally provide lactate through monocarboxylate transporters.
The connection between ALS and frontotemporal dementia centers on TDP-43 (encoded by TARDBP), which forms cytoplasmic inclusions in over 95% of ALS cases and approximately 50% of FTD cases. This pathological overlap and the discovery that mutations in TARDBP, C9ORF72, FUS, and TBK1 cause both diseases indicates a shared mechanistic basis involving disrupted RNA metabolism, protein homeostasis, and stress granule dynamics. The spectrum concept recognizes that these diseases represent varying manifestations of a common neurodegenerative process targeting specific neuronal populations.
Multiple interconnected pathological cascades contribute to motor neuron death in ALS. Oxidative stress accumulates from mitochondrial dysfunction, with mutated SOD1 proteins exhibiting altered enzymatic activity that promotes reactive oxygen species generation. SOD1 mutations (over 200 identified) cause toxic gain-of-function including mitochondrial recruitment, ER stress activation, and impairment of the proteasome and autophagy-lysosome systems. Excitotoxicity results from impaired astrocytic glutamate uptake through EAAT2, leading to excessive calcium influx through AMPA and NMDA receptors and activation of calpains and other calcium-dependent degradative enzymes.
RNA metabolism dysregulation represents a central mechanism, particularly for TDP-43 and FUS, which are RNA-binding proteins controlling alternative splicing, mRNA transport, and translation regulation. TDP-43 pathology shows cytoplasmic mislocalization, hyperphosphorylation, and aggregation, with the C-terminal fragments forming insoluble inclusions. The C9ORF72 hexanucleotide repeat expansion (GGGGCC) causes disease through both loss-of-function (reduced C9ORF72 protein expression) and gain-of-function mechanisms including the translation of dipeptide repeat proteins that accumulate in neuronal inclusions, sequestration of RNA-binding proteins, and nucleolar stress.
Autophagy and mitophagy impairment contributes significantly, with mutations in autophagy receptors OPTN and TBK1 found in ALS cases. The mTOR pathway is dysregulated, and restoring autophagy through mTOR-independent mechanisms shows therapeutic promise in animal models. Nuclear factor-κB (NF-κB) and c-Jun signaling become chronically activated in ALS, driving inflammatory gene expression in microglia and contributing to motor neuron vulnerability.
ALS diagnosis relies on clinical examination, electromyography showing widespread denervation and reinnervation patterns, and exclusion of mimicking conditions through neuroimaging and laboratory studies. The revised El Escorial and Awaji criteria provide diagnostic classifications (definite, probable, laboratory-supported probable, possible) based on clinical signs and electrophysiological evidence of upper and lower motor neuron involvement in multiple body regions. Current FDA-approved treatments include riluzole (sodium channel blocker and glutamate antagonist, providing 2–3 month survival benefit), edaravone (free radical scavenger, beneficial in early-stage patients), and the recently approved AMX0035 (combination of sodium phenylbutyrate and taurursodiol targeting ER stress and mitochondrial dysfunction).
Numerous therapeutic approaches are in clinical trials including antisense oligonucleotides targeting SOD1 (tofersen) and C9ORF72 repeat expansions, gene therapies delivering neurotrophic factors, stem cell transplantation approaches, and immunotherapies targeting TDP-43 or inflammatory pathways. Biomarker research focuses on neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) in blood and CSF, which correlate with disease progression and are being validated for diagnostic and prognostic use. The ALS research community increasingly recognizes the importance of好运娱乐平台 genetic stratification and biomarker-driven patient selection for clinical trials to improve the historically low translation rate from preclinical to clinical efficacy.
Key genes and proteins implicated in ALS include C9ORF72 (hexanucleotide repeat expansion, most common familial cause), SOD1 (superoxide dismutase 1, first identified ALS gene), TARDBP/TDP-43 (DNA-binding protein regulating RNA metabolism), FUS (Fused in Sarcoma, TLS, another RNA-binding protein), OPTN (optineurin, autophagy receptor), TBK1 (TANK-binding kinase 1, regulating inflammation and autophagy), and ATXN2 (ataxin 2, RNA granules and stress response). Related neurodegenerative diseases include Frontotemporal Dementia (FTD), Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease as overlapping or interacting proteinopathy contexts. Functional pathway connections link ALS to mitochondrial dysfunction, autophagy impairment, excitotoxicity, and neuroinflammation, providing therapeutic target opportunities across multiple mechanistic nodes.
The following diagram shows the key molecular relationships involving Amyotrophic Lateral Sclerosis (ALS) discovered through SciDEX knowledge graph analysis: